Every November 14th, World Diabetes Day is celebrated, a day dedicated to reflecting on the impact of this disease and the importance of providing solutions that improve the lives of those affected. Diabetes is a chronic condition currently affecting over 540 million people worldwide, and the number continues to rise. In the last three decades, the number of diagnoses has increased dramatically, and mortality associated with this disease has risen by 70% in just two decades.
The theme for World Diabetes Day 2024-2026, "Diabetes and Wellbeing," highlights the need for a comprehensive approach that allows people with diabetes to achieve a full life. This entails access to diagnostics, proper treatments, and necessary support to prevent and control complications. One of the most serious complications is diabetic foot ulcer, which poses a risk to the health and even the lives of those affected. In this context, Cuban treatment with Heberprot-P® provides a revolutionary alternative.
Heberprot-P®: A Cuban Solution for Diabetic Foot
Developed by Cuba's Center for Genetic Engineering and Biotechnology, Heberprot-P® is a unique treatment for diabetic foot ulcers worldwide. This medication contains recombinant human epidermal growth factor and is administered by highly trained professionals at the Institute of Angiology and Vascular Surgery and the Institute of Endocrinology in Cuba. Its use has shown remarkable effectiveness in wound healing, promoting recovery and preventing amputations.
Treatment Stages and Benefits
The Heberprot-P® treatment includes two stages:
Evaluation and preparation (4 days of hospitalization): This phase consists of consultations with specialists and a series of complementary tests. Additionally, the affected area is prepared for treatment.
Infiltration and medication treatment (26 days of hospitalization): During this phase, specialists apply Heberprot-P® directly to the lesions. The growth factor stimulates the granulation process, accelerating healing.
This treatment offers multiple benefits:
Speeds up healing and improves patients’ quality of life.
Reduces the need for surgical procedures and tissue debridement.
Minimizes ulcer recurrence and lowers hospital costs.
Decreases the risk of infections, a frequent cause of amputations in diabetic patients.
Access to Heberprot-P® Treatment
Heberprot-P® treatment is available in Cuba, and for those interested in starting the process, the Cuban Medical Services Marketer, S.A., is available to coordinate and provide assistance. Interested individuals can contact the team via email: smc@smcsalud.cu.
In a world searching for effective solutions, Cuban medical advancements in combating diabetes complications offer hope and a path to a healthier life for those affected by this disease.
By: MSc. Dr. Patricia Alonso Galbán
Marketing and Communications Specialist, CSMC, S.A.